Physiogenex will be presenting a novel obese NASH hamster model of MetALD (Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Alcohol-Associated Liver Disease) at the AASLD Liver Meeting in Boston, USA, Nov. 10-14th, 2023. This unique model will be presented during the poster session of Saturday November the 11th, poster #2464-C.
Unlike mouse and rat, the obese hamster is an original preclinical model with human-like lipoprotein/bile acids profile, that develops Metabolic Dysfunction-Associated Steato-Hepatitis (MASH), with evident hepatocellular ballooning and portal/bridging (stage 2-3) fibrosis.
Additionally, hamsters have a high preference for alcohol, unlike rat and mouse MASH models that do not stand alcohol and cannot be used for evaluating drugs targeting MetALD.
Reach out to François Briand during the meeting to learn how Physiogenex animal models and CRO services will drive your preclinical development of drugs targeting metabolic diseases to success.
Feel free to contact us if you wish to set-up an appointment with Dr. Briand and/or discuss your drug development projects with us.
Physiogenex is a leading preclinical research organization providing non clinical services in metabolic disorders and complications.
We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We have a strong expertise on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis), cardiovascular and renal complications.